Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.

Autor: Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Neuroscience Interdepartmental PhD Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, California.; Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, California.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Hagiwara A; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan., Morris CJ; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Medical Scientist Training Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Cho NS; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, California.; Medical Scientist Training Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Oshima S; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Sanvito F; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Oughourlian TC; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Neuroscience Interdepartmental PhD Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Telesca D; Department of Biostatistics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Raymond C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Abrey LE; F. Hoffman-La Roche, Ltd., South San Francisco, California., Garcia J; F. Hoffman-La Roche, Ltd., South San Francisco, California., Aftab DT; Exelixis, Alameda, California., Hessel C; Exelixis, Alameda, California., Rachmilewitz Minei T; VBL Therapeutics, Modi'in, Israel., Harats D; VBL Therapeutics, Modi'in, Israel., Nathanson DA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Cloughesy TF; UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, California.; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Oct 13; Vol. 29 (20), pp. 4186-4195.

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

Autor: Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK. thomas.powles1@nhs.net., Choueiri TK; Dana-Farber Cancer Center, Boston, MA, USA., Motzer RJ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jonasch E; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pal S; City of Hope National Medical Center, Duarte, CA, USA., Tannir NM; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Signoretti S; Brigham and Women's Hospital, Boston, MA, USA., Kaldate R; Exelixis, Inc, Alameda, CA, USA., Scheffold C; Exelixis, Inc, Alameda, CA, USA., Wang E; Exelixis, Inc, Alameda, CA, USA., Aftab DT; Exelixis, Inc, Alameda, CA, USA., Escudier B; Gustave-Roussy, Villejuif, France., George DJ; Duke Cancer Institute, Durham, NC, USA.

Publikováno v: BMC cancer [BMC Cancer] 2021 Aug 07; Vol. 21 (1), pp. 904. Date of Electronic Publication: 2021 Aug 07.

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

Autor: Ellingson BM; UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Aftab DT; Exelixis, South San Francisco, California., Schwab GM; Exelixis, South San Francisco, California., Hessel C; Exelixis, South San Francisco, California., Harris RJ; UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Departments of Radiological Sciences and Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Woodworth DC; UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Departments of Radiological Sciences and Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Leu K; UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Departments of Radiological Sciences and Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Chakhoyan A; UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Departments of Radiological Sciences and Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Raymond C; UCLA Brain Tumor Imaging Laboratory, Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Departments of Radiological Sciences and Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Drappatz J; Department of Neurology and Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., de Groot J; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Prados MD; Department of Neurosurgery, University of California San Francisco (UCSF), San Francisco, California., Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schiff D; Neuro-Oncology Center, University of Virginia Health System, Charlottesville, Virginia., Chamberlain M; Department of Neurology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington., Mikkelsen T; Henry Ford Health System, Detroit, Michigan., Desjardins A; Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina., Holland J; Exelixis, South San Francisco, California., Ping J; Exelixis, South San Francisco, California., Weitzman R; Exelixis, South San Francisco, California., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Cloughesy TF; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Publikováno v: Neuro-oncology [Neuro Oncol] 2018 Sep 03; Vol. 20 (10), pp. 1411-1418.